These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic value of T lymphocyte subset ratios for renal transplant survival in patients on different immunosuppressive regimens.
    Author: Henny FC, van Es A, Oljans PJ, Baldwin WM, Tanke HJ, van Es LA, Paul LC.
    Journal: Clin Exp Immunol; 1986 Aug; 65(2):373-80. PubMed ID: 3024886.
    Abstract:
    Previously we reported that the pre-transplant and pre-rejection OKT4/OKT8 ratio can be used to predict renal allograft survival. Patients on azathioprine (Aza) and low-dose steroids (St) with a pretransplant ratio less than or equal to 1.6 exhibited a 6-month graft survival of 33% compared with 79% for those with a ratio greater than 1.6 (P = 0.02). Furthermore, 100% of the rejection episodes treated with high doses of prednisone in patients with a prerejection ratio less than or equal to 1.6 were irreversible in comparison with only 10% for patients with a ratio greater than 1.6 (P less than 0.001). In the present study, we investigated the prognostic value of the OKT4/OKT8 ratio for patients who received rabbit antithymocyte globulin (RATG) as anti-rejection therapy or cyclosporin A (CsA) as basic immunosuppressive therapy. No correlation was found between the pre-transplant OKT4/OKT8 ratio and 6-month graft survival for either treatment group because of an improved graft survival among patients with a pretransplant ratio less than or equal to 1.6 (78% for patients who received RATG and 85% for CsA-treated patients). For Aza-treated patients with an OKT4/OKT8 ratio less than or equal to 1.6 at the time of rejection, rejection episodes that were treated with RATG were reversible in 78% of the cases, whereas among CsA-treated patients rejection episodes treated with high doses of prednisone were reversible in 72% of the cases. No significant differences in graft survival or reversibility of rejection episodes between patients with a pre-transplant or prerejection OKT4/OKT8 ratio greater than 1.6 were found. Furthermore, in both the CsA and the Aza-treated patients (with or without RATG), the OKT4/OKT8 ratio had decreased significantly 3 months after transplantation. This decrease was associated with cytomegalovirus infections rather than the type of immunosuppressive therapy.
    [Abstract] [Full Text] [Related] [New Search]